{"version":"1.0","type":"link","title":"Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.","author_name":"Huang D 외","author_url":"https://prs-insight.online/author/Huang%20D","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/93448","thumbnail_width":1200,"thumbnail_height":630}